Responses
Other responses
Jump to comment:
- Published on: 13 April 2016
- Published on: 13 April 2016
- Published on: 13 April 2016
- Published on: 13 April 2016Author's reply to: Expensive antirheumatic drugsShow More
Dear Editor
We very much welcome the thoughts of Drs Geborek and Saxne on our recent article,[1] and agree that a scientific approach should be taken to the synthesis of evidence in decision models. Our analysis is not the last word but rather the first decision analysis of adalimumab. The contention stems from the limitations in the evidence base. In this regard, to wait for all the evidence to be collected (possibly m...
Conflict of Interest:
None declared. - Published on: 13 April 2016Expensive antirheumatic drugsShow More
Dear Editor
The article "Cost effectiveness of adalimumab in the treatment of patients with moderate to severe rheumatoid arthritis in Sweden" by Bansbeck, Brennan, and Ghatnekar [1] deals with an important subject, i.e. is it justifiable from a cost-effectiveness point of view to use tumour necrosis factor (TNF) inhibitors in rheumatoid arthritis (RA).
We acknowledge that the authors have used data from...
Conflict of Interest:
None declared. - Published on: 13 April 2016Expensive antirheumatic drugs - final replyShow More
Dear Editor,
We have read the reply from the authors to our letter. As a final remark we would like to repeat our previous statement: “From a clinician’s perspective we think that health economic analyses in RA should always be done with intimate knowledge of the patient cohort on which the calculations are based. Any projection and modelling in other settings must be carried out with great care in close collabora...
Conflict of Interest:
None declared.